Citigroup Maintains Neutral on Galera Therapeutics, Lowers Price Target to $0.25
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Yigal Nochomovitz has maintained a Neutral rating on Galera Therapeutics (NASDAQ:GRTX) and lowered the price target from $0.4 to $0.25.
August 29, 2023 | 4:34 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Citigroup has maintained a Neutral rating on Galera Therapeutics and lowered the price target from $0.4 to $0.25.
The lowering of the price target by Citigroup indicates a potential decrease in the stock's value. This could lead to a negative short-term impact on Galera Therapeutics' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100